PPPrakash Peddi

Prakash Peddi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prakash Peddi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Gary Von Burton

    LSU Health Sciences Center, Shreveport, LA

    5 shared publications
  • Quyen D. Chu

    Department of Surgery, Division of Surgical Oncology, Louisiana State University Health Science Center-Shreveport, Shreveport, Louisiana

    4 shared publications
  • Run-Hua Shi

    North China Electric Power University

    4 shared publications
  • Meijiao Zhou

    Louisiana Tumor Registry & Epidemiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, USA; School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA

    3 shared publications
  • Shashank Cingam

    Louisiana State University Health Sciences Center, Shreveport, LA

    3 shared publications
  • Amol Takalkar

    Center for Molecular Imaging and Therapy, Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana, USA

    2 shared publications

Latest Publications

  • Open Access

    Iatrogenic constipation from barium blockade: A case report

    by Shajadi Pathan, Taras Benzar, Samip Master, Prakash Peddi

    Barolith, a mixture of inspissated barium and feces, is a rare complication of barium‐contrast studies that lead to intestinal obstruction. With the high morbidity associated with barolith impaction, we recommend that physicians be more aware of complications, increase prompt diagnosis, and initiation of laxatives once discovered.


  • Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines

    by Prakash Peddi, Samip R. Master, Ashish D. Dwary, Hari P. Ravipati, Abhishek H. Patel, Avinash Pasam, Pavan K. Katikaneni, Runhua Shi, Gary V. Burton, Quyen D. Chu

    Anthracycline‐based chemotherapy is widely used in the management of breast cancer. Despite the lack of clinical evidence, obtaining prechemotherapy left ventricular ejection fraction (LVEF) by echocardiogram or multigated acquisition scan is a widely adopted practice throughout the world. We present here the results of a retrospective analysis of breast cancer patients who had LVEF measurements in anticipation of an anthracycline chemotherapy to determine whether predefined cardiac risk factors predicted for poor cardiac function. Retrospective data were analyzed from 482 female breast cancer patients in whom LVEF was measured before starting anthracycline‐based chemotherapy. Baseline demographics and multiple risk factors associated with congestive heart failure were collected. Twenty‐six possible risk factors for CHF were defined, and the frequency of finding an abnormal LVEF as a function of total risk factors was assessed. Statistical tests include chi‐squared and logistic regression analysis. The median age of the study population was 52 years. The original chemotherapy plan was changed in 7 patients (1.45%) based on LVEF findings, all of which had asymptomatic LV dysfunction (LVEF ranging 40%‐50%). In 32 patients, despite normal LVEF results, anthracyclines were omitted secondary to prior cardiac issues. In 17 patients where LVEF was reported normal, anthracyclines were skipped based on patient's preference, tumor characteristics, or upstaging of the cancer based on imaging studies. No patient with ≤2 risk factors had an abnormal LVEF (N = 350). The probability of finding an abnormal LVEF in patients without any cardiac risk factors is extremely rare. Skipping baseline LVEF assessment may be an option in some patients with no cardiac risk factors undergoing anthracycline‐based chemotherapy.


  • Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma

    by Quyen D. Chu, Meijiao Zhou, Prakash Peddi, Kaelen L. Medeiros, Gazi B. Zibari, Hosein Shokouh-Amiri, Xiao-Cheng Wu


  • Open Access

    Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review

    by David Sommerhalder, Amol M. Takalkar, Rodney Shackelford, Prakash Peddi

    Key Clinical Message: Although tumor lysis syndrome is well described, it is rarely seen or suspected in solid malignancies. Early recognition of this entity is paramount in reducing morbidity and mortality. Treating physicians should be aware of this possibility in solid tumor patients with either bulky disease or extensive liver involvement.


  • Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base

    by Quyen D. Chu, Meijiao Zhou, Kaelen L. Medeiros, Prakash Peddi, Xiao Cheng Wu

    Background: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. Materials and Methods: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy. Patients were classified into two groups based on the time of CALGB 9343 publication: (i) pre-CALGB (up to 2004), and (ii) post-CALGB (2005-2012). Clinicopathological and sociodemographic variables were compared between pre- and post-CALGB groups. Chi-square and multivariable logistic regression were employed, with the omission of adjuvant RT as the primary outcome in the regression analysis. Results: Radiation therapy usage decreased by 4.1% after CALGB publication (on average 71.6% pre-CALGB vs. 67.5% post-CALGB; p<0.0001). Almost one-third of women aged ≥85 years received RT in the post-CALGB group. In a multivariable model, the variables significantly associated with increased odds for omission of RT in the post-CALGB group were: advanced age, African-American, increased great circle distance, therapy under academic research program, residents of East South-Central region, living in a rural population <2,500 not adjacent to a metropolitan area, low income level, Medicaid recipients, high comorbidity index, small tumor, well-differentiated histology, residual tumor, and lack of receipt of chemotherapy and anti-hormonal therapy. Conclusion: During the study period, the CALGB trial publication had a minimal impact on the rate of adjuvant RT use among elderly women with small, ER-positive breast cancers. Significant variation in RT usage existed across sociodemographic strata.


  • Follicular dendritic sarcoma masquerading as fibrosing mediastinitis

    by Shashank Reddy Cingam, Majd Al Shaarani, Amol Takalkar, Prakash Peddi

    Fibrosing mediastinitis (FM) is a rare disorder resulting from abnormal immunological-mediated fibro-proliferative reaction in the mediastinum. Here, we describe a case of a 46-year-old female with an incidentally found 11×9 cm posterior mediastinal mass. Multiple biopsies of this unresectable, 18-fluorodeoxyglucose avid mass revealed marked fibrosis without any evidence of malignancy, suggesting idiopathic fibrosing mediastinitis as our initial diagnosis. Multiple interventions including a trial of steroids, fluconazole, and azathioprine to target fibrosing mediastinitis were not successful. Repeat biopsy was consistent with primary mediastinal follicular dendritic cell sarcoma. The manuscript highlights the heightened need for suspecting occult malignancies in cases of FM presenting with an indeterminate cause.


  • Primary brain tumor and risk of venous thromboembolism.

    by Ashish Dutta Dwary, Ankita Gupta, Gary Von Burton, Prakash Peddi

    E13518 Background: Venous thromboembolism (VTE) is frequently associated with primary brain tumors (PBT). Brain tumors have been associated with higher rates of VTE in multiple studies. Studies comparing VTE incidence in meningioma (MEN), astrocytoma (AA), oligodendroglioma (OG) and glioblastoma multiforme (GBM) are lacking. The aim of this retrospective study is to report the VTE outcomes in all of the above brain tumors. Methods: Retrospective data from 476 patients with PBTs diagnosed between 1995-2015 at Louisiana State University Health Sciences Center-Shreveport was analyzed. The incidence of VTE (deep vein thrombosis or pulmonary embolism) was studied in these patients. Results: Out of 476 patients, 298 were females and 179 were male. One hundred and twenty seven (127) patients had GBM, 52 had AA, 33 had OG and 264 had MEN. Only two patients out of 264 with MEN had VTE (one patient had central line catheter associated DVT). VTE incidence did not correlate with the type of primary treatment i.e surgery verses radiation verses observation in this patient group. The incidence of VTE was 7.8 % in GBM patients. The risk of VTE in AA and OG patients were 7.7% and 9.0 % respectively. The VTE event in the OG, AA and GBM occurred during all phases of treatment including inpatient hospitalization for surgical resection, during concurrent chemo-radiation and in maintenance phase. Biopsy versus partial resection versus complete resection of GBM didn’t correlate with VTE occurrence. Conclusions: VTE is prevalent among adult patients with both low and high grade glial tumors. The thrombotic events occur during all phases of therapy indicating hypercoagulable state for many patients. Life-long anticoagulation may be necessary in these patients with thrombotic events. Thrombotic events in patients with MEN, however, are rare ( < 1%). MEN do not appear to be a hypercoagulable and life-long anticoagulation is probably unnecessary in those with VTE.


  • Triple negative breast cancer (TNBC): Analysis of age and stage distribution and survival between African American and Caucasian women in a predominant low-income population.

    by Sheeba V. Tano, Mindie Michelle Kavanaugh, Prakash Peddi, Richard P. Mansour, Runhua Shi, Gary Von Burton

    E12586 Background: Triple negative breast cancers (TNBC) represent roughly 15% of all breast cancer and are associated with decreased overall survival. A higher incidence of TNBC has been seen in younger and African American patients. We investigated the effect of age and race relative to outcomes of patients with TNBC seen at a state charity hospital system. Methods: This retrospective review identified 194 pts with TNBC diagnosed between 1993-2011 at LSUHSC-Shreveport, a state charity hospital. TNBC was defined as ER/PR both


  • Open Access

    Reversal of isolated 20q deletion with vitamin B12 replacement in a patient with pernicious anaemia

    by Shashank Reddy Cingam, Nebu Koshy, Diana Veillon, Prakash Peddi

    Severe vitamin B12 deficiency is well known to cause morphological alterations in bone marrow. In rare instances, these myelodysplastic and megaloblastic changes can coexist with cytogenetic abnormalities. Here, we report a case of a 38-year-old African-American woman with pernicious anaemia, who was found to have an isolated 20q deletion and which resolved after vitamin B12 replacement. We also discuss various mechanisms in which vitamin B12 deficiency can lead to chromosomal abnormalities. A literature review is also performed to evaluate various other chromosomal aberrations associated with B12 deficiency.


  • Open Access

    Recurrent Malignant Melanoma Presenting as Isolated Pleural Metastases in a Patient with Chronic Lymphocytic Leukemia

    by Kartik Anand, Shashank Cingam, Prakash Peddi

    Isolated pleural metastasis with pleural effusion is a rare occurrence in malignant melanoma. We report an unusual case of a patient with chronic lymphocytic leukemia (CLL) and recurrent pleural effusions. The pleural fluid cytology and immunohistochemistry profile were consistent with the diagnosis of CLL. However, chemotherapy with pentostatin, cyclophosphamide, and rituximab did not result in any meaningful clinical response. A video-assisted thoracoscopic surgery and biopsy of the affected nodular parietal layer of the pleura were consistent with malignant melanoma. Our case underlines the importance of having a suspicion for secondary causes of effusion in patients with CLL. We briefly discuss the mechanisms of an increased incidence of secondary cancers in CLL and the diagnosis of isolated pleural metastases in malignant melanoma.